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Abstract: Aquaporins (AQPs) are a family of widely distributed membrane-inserted water channel proteins providing a 
pathway for osmotically-driven water, glycerol, urea or ions transport through cell membranes and mechanisms to control 
particular aspects of homeostasis. Beside their physiological expression patterns in Central Nervous System (CNS), it is 
conceivable that AQPs are also abnormally expressed in some pathological conditions interesting CNS (e.g. neurodegen-
erative diseases) in which preservation of brain homeostasis is at risk.  
The purpose of this review was to take in consideration those neurodegenerative diseases in whose pathogenetic processes 
it was possible to hypothesize some alterations in CNS AQPs expression or modulation leading to damages of brain water 
homeostasis. 
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1. ALTERED WATER HOMEOSTASIS IN NEU-
RODEGENERATIVE DISEASES 
  Several million people world-wide are affected by neu-
rodegenerative disease, a heterogeneous group of diseases 
affecting specific areas of Central Nervous System (CNS) 
and leading to a gradual and progressive cognitive or move-
ment impairments, depending on the type of neuronal cells 
undergoing selective degeneration [11]. The majority of 
these pathological conditions are age-related: their fre-
quency, in fact, has increased in the last decades, together 
with an increased life expectancy of the individuals [61]. 
Neuronal damage and oxidative stress (primary events in the 
development of these kinds of disorders) lead to increased 
production of pro-apoptotic and pro-inflammatory cytokines 
as well as altered homeostasis of water, extracellular ions 
and aminoacid neurotransmitters. In consequence of the 
damaged brain homeostasis observed in many of these pa-
thologies, some authors hypothesized a possible role for Aq-
uaporin (AQP) family members in their pathogenetic mecha-
nisms. The purpose of this paper was to review the recent 
findings about the involvement of these water channel pro-
teins in the developmental processes of these neurodegenera-
tive diseases, focusing on Neuromyelitis Optica (NMO), 
Alzheimer’s Disease (AD), Parkinson’s Disease (PD), 
Amyotrophic Lateral Sclerosis (ALS) and Transmissible 
Spongiform Encephalopathies (TSE).  
2. NEUROMYELITIS OPTICA  
  Inflammatory demyelinating diseases of the CNS occur 
throughout the world and are the foremost reason for non-
traumatic neurological disability in young, white adults [76]. 
Neuromyelitis optica (NMO) was first described in the late 
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th century by Eugène Devic and the syndrome came to be 
eponymously called Devic’s disease [15, 16]. NMO is de-
fined as a severe monophasic syndrome that is characterized 
by near-simultaneous bilateral optic neuritis (ON), acute 
transverse myelitis and inflammatory demyelination with a 
selective involvement of the optic nerve and the spinal cord 
where affects gray and white matter, causing blindness and 
paralysis [99]. Although NMO has been classified as a sub-
type of multiple sclerosis (MS) for many years, it is now 
clear that it has distinct clinical and pathological features. 
Neuropathologic studies demonstrate that NMO is character-
ized by distinctive “vasculocentric” pathology with promi-
nent perivascular immunoglobulin deposition (IgG and IgM) 
and evidence of activation of complement lytic pathway, 
invoking B cell participation in the disease process [56, 100]. 
These observations further support an auto-antibody medi-
ated pathogenesis for NMO. 
2.1. Discovery of Specific Auto-Antibodies Against AQP4 
in NMO Patients 
  In 1998, the observation that patients with NMO fre-
quently had multiple autoimmune disorders and a variety of 
non organ-specific auto-antibodies prompted a search for a 
specific auto-antibody marker of NMO. Lennon and col-
leagues [54] described an IgG, the presence of which was 
73% sensitive and 91% specific for clinically defined NMO. 
The detection of NMO specific serum auto-antibodies, col-
lectively known as NMO-IgG, helps to allows early diagnos-
tic distinction between NMO and MS [54, 56]. Typically, 
NMO-IgG is detected at the first attack of myelitis or ON, 
suggesting that the antibody is more likely an integral part of 
the pathogenesis of the disease rather than an epiphenome-
non of the tissue injury, but longitudinal data are limited and 
preliminary.  
  Accumulating evidences reveal that NMO-IgG localizes 
to blood-brain barrier (BBB) [54]: an indirect immunofluo-
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sections with NMO patient’ sera and antibodies specific for 
the endothelial marker factor VIII, the reactive-astrocyte 
marker glial fibrillary acidic protein (GFAP) or the extracel-
lular matrix protein laminin, has suggested that the main 
target antigen is in astrocytes located adjacent to the BBB 
[54]. In white and grey matter of the cerebellum, midbrain, 
and spinal cord, NMO-IgG bound in a linear pattern along 
pial membranes, extending into the Virchow-Robin spaces, 
the abluminal surface of cerebral microvessels, and the sub-
pial region with a mesh pattern. NMO-IgG bound to an anti-
gen in the abluminal face of cerebral microvessels, an area 
represented by astrocytic foot processes. Moreover, its par-
tial colocalization with laminin [54] is consistent with the 
auto-antigen being a component of the glia limitans at the 
BBB [66]. An independent pathologic study had meanwhile 
recognized an immunohistochemical pattern of immuno-
globulin and complement deposition detected around small 
vessels of autopsied spinal cord tissues of patients with 
NMO-IgG [56] that was reminiscent of the pattern of immu-
nostaining of serum from NMO patients to the abluminal 
surface of penetrating microvessels in the mouse brain   
substrate.  
  Recently, the target antigen of NMO-IgG has been   
identified as the mercurial-insensitive water channel protein 
AQP4 which is the dominant water channel within the CNS 
[53].  
  In astrocytic end-feet, AQP4 is closely associated with 
the cytoskeleton complex. To exclude a primary effect on 
one of these cytoskeletal proteins as targets, lysates of the 
AQP4 and control transfected cell lines were immunopre-
cipitated with antibodies specific for -syntrophin,  -
dystroglycan, and dystrophin (Dp71) as well as antibodies 
specific to AQP4. Only NMO-IgG or anti-AQP4 antibodies, 
but not antibodies to other cytoskeletal elements were able to 
immunoprecipitate the green fluorecent protein (GFP)-AQP4 
fusion protein. Then, to determine whether the NMO antigen 
is restricted to the CNS, NMO-IgG-positive patients' sera 
were tested on sections of normal non-nervous mouse tis-
sues. In contrast to the characteristic intense staining of pial 
and microvascular elements in the brain, NMO-IgG did not 
bind to any vascular or visceral autonomic neural elements in 
these organs. The distribution of NMO immunoreactivity 
showed the water channel protein, AQP4, as a candidate 
antigen. Moreover, using sera from NMO-IgG positive pa-
tients on brain tissue obtained from AQP4 knock-out mice, 
Lennon and colleagues [53] showed that neither human   
serum IgG from NMO patients nor rabbit anti-AQP4 IgG 
bound detectably to the AQP4 knock-out mouse brain   
tissues (Fig. (1)). 
  Furthermore, to demonstrate selective binding to mem-
branes of AQP4 transfected cells, stably transfected human 
embryonic kidney cell line (HEK-293) expressing a trans-
gene encoding full-length AQP4 and plasmid encoded GFP 
were created. Neither patients’ nor controls' IgG bound to the 
HEK-293 cells that were not transfected with the AQP4 con-
taining vector; however, IgG in the sera of NMO patients 
stained the plasma membrane of AQP4-transfected cells, 
consistent with the known expression pattern of AQP4 in 
cells. In addiction, Jarius and colleagues [41] have confirmed 
that a cell-based or a novel fluorescence-based immunopre-
cipitation assay that employs recombinant human AQP4 
coupled to GFP has higher sensitivity and specificity for 
NMO than does the NMO-IgG assay. The increased sensitiv-
ity of AQP4 assays compared with NMO-IgG testing sug-
gests that AQP4 is the main, or possibly the only, target for 











Fig. (1). Immunofluorescence reveals NMO-IgG co-localization 
with AQP4 in mouse tissues. (A) Brain Virchow-Robin space 
(pial-astrocyte interface): NMO-antigen (green, fluorescein-
conjugated IgG), AQP4 water channel protein (red, rhodamine-
conjugated IgG); merged images yellow. (B)  WT mouse brain 
binds NMO-IgG (panel 1) in a pattern that is indistinguishable from 
its binding of AQP4-specific IgG (panel 4); pia, subpia, and mi-
crovessels are stained. However, AQP4 knock-out mouse brain 
(null) did not bind NMO-IgG (panel 2), and the serum of a control 
patient who had neuropsychiatric disease did not bind to WT brain 
(panel 3). Figures from Lennon et al., [53], reprinted with permis-
sion of The Rockefeller University Press. 
  Taken together, these discoveries make NMO the first 
inflammatory demyelinating disorder of the CNS in humans 
in which a specific target for an immune reaction has been 
identified. NMO-IgG is now utilized as a clinical serological 
test for this disease and promises to provide substantial in-
sight into the pathogenesis of NMO. Recent data, in fact, 
have confirmed that assays for anti-AQP4 antibodies are 91-
100% specific for differentiating NMO from conventional 
MS [100]. 
2.2. AQP4 Auto-Antibodies and NMO Pathogenesis 
  Recently, widespread absence of detectable AQP4 in 
spinal cord tissue of NMO lesions has been demonstrated by 
several groups [65, 80, 85]. Misu and colleagues [65] con-
ducted an immunohistochemical analysis that revealed loss 
of AQP4 in 90% of the acute and chronic NMO lesions, 
which were more pronounced in the active perivascular le-
sions where immunoglobulins and complements were depos-
ited. In addiction, Lucchinetti [56] and Roemer [80] and their 
groups have independently performed detailed comparative 
study between NMO and MS lesions: in particular, in con-
trast to NMO, they revealed that AQP4 immunoreactivity 
was variable in MS lesions (AQP4 is diffusely increased in 
the white matter of active lesions, whereas chronic inactive 
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  Moreover, two pathologic patterns in NMO, both of 
which were associated with loss of AQP4 immunoreactivity 
were described [39]. The first and most prevalent lesion pat-
tern involves the spinal cord and optic nerves. Loss of AQP4 
occurs in the context of vasculocentric immune complex 
deposition, active demyelination and vascular hyperplasia 
with hyalinization. These lesions involve both grey and 
white matter in the spinal cord. Also in the second, less fre-
quent, lesion type AQP4 loss was associated with vasculo-
centric IgG and IgM deposits, complement activation, and 
tissue rarefaction, but there was no evidence of demyelina-
tion [80]. In summary, the intriguing report by Roemer and 
colleagues [80], describing loss of AQP4 in the absence   
of demyelination or necrosis suggests that binding of anti-
body to AQP4 may be the initial pathogenic event in NMO 
lesions. 
  In a comparable study, Misu and colleagues [65] showed 
some NMO lesions in which myelinated fibers were rela-
tively preserved despite the loss of AQP4 staining, suggest-
ing that the loss of AQP4 did not reflect necrosis and cell 
loss. These findings suggested that AQP4 loss may be the 
initial event in NMO lesions. 
  The limited access of circulating IgG to the extracapillary 
space in the CNS would only permit interaction of NMO-
IgG with AQP4 at the glia limitans of BBB: in consequence 
of these findings, many authors suggest the perivascular 
space as the primary target site of the pathogenic process. 
Current hypotheses concerning the pathogenesis of NMO are 
divergent: interaction between NMO-IgG and AQP4 could, 
in turn, activate complement produced locally by astrocytes 
[68] or cross-link AQP4, thereby perturbing water homoeo-
stasis in the CNS [53].  
  On the basis of the immunopathological observations, a 
cascade reaction initiated by the presence of a peripheral 
antibody directed against AQP4 activating the classical com-
plement pathway was proposed [100]. Activated macro-
phages, eosinophils and neutrophils generate cytokines, pro-
teases and free radicals leading to vascular and parenchymal 
damage. Increased vascular permeability could cause further 
parenchymal destructive processes via secondary ischemia, 
leading to the liberation of novel antigens that may further 
extend the immune response. 
  Other auto-antibodies, in fact, have been found in NMO 
patient sera and cerebrospinal fluid (CSF) (anti-myelin oli-
godendrocyte glycoprotein (MOG) antibodies) [12, 31]: 
these latter auto-antibodies likely represent a response to 
neo-antigen liberated from dead cells and thus are not the 
initial cause of NMO [31, 50]. 
  Although it has been suggested that AQP4 auto-
antibodies cause NMO, probably by inhibiting AQP4, [59, 
64] other authors [87] keep a more skeptical view pondering 
that this causality still lacks definite proof, as NMO has not 
been produced in experimental animals through administra-
tion of the antibody. In addition to that, a number of ques-
tions remain to be answered: why other organs which highly 
express AQP4 (e.g. kidneys, lung, inner ear and intestine) are 
not affected in the disease; why the lesions are predomi-
nantly located in the spinal cord and optic nerves, although 
AQP4 is ubiquitously expressed throughout the nervous sys-
tem; what is the preceding event opening the BBB to allow 
the peripheral anti-AQP4 antibody enter the brain; why a 
NMO-like phenotype does not follow AQP4 deletion in 
mice. 
3. ALZHEIMER’S DISEASE 
  Alzheimer’s disease (AD) is nowadays the most wide-
spread form of senile dementia in the Western countries. AD 
is clinically characterised by a gradual onset with a progres-
sive and irreversible cognitive decline: memory impairment 
appears in the earliest stage of the disease although patients’ 
motor and sensory functions are usually not affected until 
later stages [13]. Only the post-mortem microscopic exami-
nation reveals the critical features of AD: the progressive 
accumulation of senile plaques (mainly composed of amy-
loid- (A)), neurofibrillary tangles (NFTs) (in which the 
main component is hyper-phosphorylated tau) and neuropil 
threads in the brain [19]. All these neuropathological   
hallmarks cause nervous cell death, cortical and sub cortical 
atrophy and so damage nervous system functions. AD is   
considered a systemic disease progressively affecting not 
only the entorhinal cortex, limbic structures and neocortex 
[9], but also the basal nucleus of Meynert (the main source 
of the cortical cholinergic innervations), thalamus and brain 
stem.  
  Nowadays, the aetiology of AD remains unknown. It is 
probable that many concomitant factors (both genetic and 
environmental factors) are relevant in the AD pathogenesis. 
3.1. Chronically Imbalanced Cholinergic Neurotransmis-
sion and Water Motion in CNS 
  Chronically imbalanced cholinergic neurotransmission 
affects [69] and accompanies AD [98]. However, it remained 
unclear whether imbalanced cholinergic neurotransmission 
may by itself lead to chronic brain damages and, if it does, 
which molecular, cellular, and physiological pathways are 
involved.  
  To approach this question, Beeri and colleagues [7] used 
transgenic mice with neuronal over-expression of synaptic 
acetylcholinesterase (AChE-S) of human origin. These mice 
display a complex central and peripheral phenotype includ-
ing fluctuations of brain acetylcholine (ACh) levels, elevated 
high affinity choline transport, and accelerated stress-related 
neuropathology associated with progressive cognitive dete-
rioration [86]. Prolonged AChE overexpression occurs in the 
mammalian brain under psychological stress [62], and vari-
ous studies provide evidence that such stress can induce 
BBB disruption [84, 89] via yet unknown mechanisms. The 
authors showed with brain image analysis significant 
changes in the brain’s diffusion and perfusion parameters 
strengthen the notion of alterations in water mobility and 
BBB integrity under cholinergic imbalances. Similar to ani-
mal models of ischemia or stroke with elevated AQP4, 
AchE-S transgenic mice displayed lower baseline motion of 
water in CNS [52, 83] than their age-matched controls. 
AQP4 is expressed at higher cellular levels in these animals, 
but in a similar number of cells in the transgenic and wild-
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especially intriguing: changes observed in the expression of 
ion and water channels could explain the differences in the 
mobility of water and ions into and out of brain cells and in 
BBB integrity. AQP4 levels in microvascular endothelium 
increase in diseases associated with BBB disruption [94]   
and its absence protects the mouse brain from damages   
characteristic of BBB malfunctioning [58].  
3.2. AQP4 and Neurovascular Unit in AD Brains  
  The blood-brain interface has been described as a func-
tional unit commonly called the neurovascular unit (NVU) 
[1, 34]. A primary function of this specialized region of the 
brain is to regulate the ionic composition of the extracellular 
milieu by altering local cerebral blood flow and transport 
across the BBB. The NVU is well suited for this role since 
astrocyte end-feet are highly enriched with potassium chan-
nels and water channels [2]. Astrocytes of NVU are known 
to maintain extracellular potassium concentrations in the 
brain by a process termed “potassium siphoning” [48, 77]. 
Thus, it is reasonable to predict that changes in potassium 
channel (Kir 4.1 channels) function may alter brain homeo-
stasis leading to brain impairment. Water movement via  
the AQP4 water channel localized to astrocyte end-feet 
maintains osmotic balance and promotes effective potassium 
siphoning [71]. 
  Many accompanying pathologies probably contribute to 
progression of AD, including cerebrovascular pathology 
[75]. Blood flow changes including hypoperfusion have been 
observed in AD [18]. In addiction, accumulation of A in the 
cerebral vasculature is associated with cerebral amyloid an-
giopathy (CAA) and has been reported to be present in 78%-
98% of all autopsied AD cases [45].  
  Moreover, arterioles and capillaries in AD brains are 
morphologically characterized by atrophy, swelling and in-
creased pynocitic vesicles in endothelial cells, atrophy and 
irregularities of smooth muscle fibres, thickening and local 
disruption of basement membranes and occasional swelling 
of astrocytic end-feet [24, 29, 34]. All these observations 
lend support to the idea that water and nutrient transport may 
be impaired in AD.  
  In a recent paper, Wilcock and colleagues [97] studied 
the effects of amyloid accumulation at cerebral vessels on 
the NVU, using a transgenic mouse model that show amy-
loid deposition, tau pathology and neuronal loss. Transgenic 
mice with high levels of CAA have significant reductions in 
AQP4 and Kir4.1 positive staining associated with the blood 
vessels. A potential explanation for the loss of AQP4 and 
Kir4.1 channels is that they share a common anchoring pro-
tein that is affected by vascular amyloid deposition: the 
Dp71 dystrophin protein, localized on perivascular astrocytes 
[40]. Dystrophin is associated with dystroglycan, which in 
turn, associates with syntrophins: genetic deletion of syntro-
phin has resulted in mislocalization of AQP4 [72] and de-
creased perivascular Kir4.1 channel expression [25]. Thus, 
changes in dystrophin levels and function may, in part,   
explain the loss of AQP4 from the astrocyte end-feet as well 
as the reduction in levels of Kir4.1 channels in mice that 
express high levels of CAA. Moreover, in support to this 
hypothesis, Wilcock and colleagues found that gene expres-
sion of Kir4.1, AQP4 and dystrophin were significantly   
reduced also in human post-mortem diagnosed AD brain 
with moderate and severe CAA.  
  Overall, these data point to a critical role for the NVU in 
AD [34, 105]: vascular amyloid deposition results in mislo-
calization of AQP4 expression and changes in expression 
levels of specific potassium channels, both of which are 
critical components of physiological systems designed to 
maintain the brain external milieu. 
3.3. AQP1 and AD 
  A recent study showed that the expression of AQP1 but 
not that of AQP4 is augmented in cortical astrocytes of AD 
brains [78]. Supporting this view, previous clinical studies 
showed that brain ion and water homeostasis is profoundly 
disturbed in AD [33].  
  In investigating the relationship between A deposition 
and astrocytic AQP1 expression in the motor cortex and hip-
pocampus of AD patients, Misawa and colleagues [63] found 
that the great majority of AQP1-expressing astrocytes were 
located in close proximity to A plaques in AD brains (Fig. 
(2)). In another study, Dohke and Turner [17] analyzed the 
molecular interaction between AQP1 and A in a transient 
expression system of HEK293 cells in vitro, reporting AQP1 
and A1-42 co-localization on the cell-surface membrane and 









Fig. (2). Multipolar fibrillary astrocytes express AQP1 in the 
cerebral motor cortex of AD. (a) AQP1 (brown) and Aß (red). 
Multipolar fibrillary astrocytes expressing an intense AQP1   
immunoreactivity are often located on the top of Aß deposition; (b) 
Aß (red) in the hippocampus of the patient with AD. Figures from 
Misawa et al., [63], reprinted with permission of Springer. 
  A number of previous studies showed that astrocytes are 
activated by A itself in AD brains [70, 101]: these observa-
tions suggest the hypothesis that A deposition might cause 
abnormal brain water homeostasis by interfering with astro-
cytic water channel function. To evaluate the hypothesis 
described above, a recent study using combined Western 
blotting and immunohistochemistry in a selected number of 
sporadic and familial AD showed that the levels of AQP1 
expression are significantly elevated in the frontal cerebral 
cortex of AD patients. Interestingly, these changes occur at 
early stages of the disease with minimal deposition or diffuse 
plaques of A, where reactive astrocytes express a cell-
surface punctuate AQP1 immunoreactivity [78]. This study 
also revealed the lack of uniformity of AQP1 expression 
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stained with anti-AQP1 antibodies, whereas AQP1 expres-
sion was marked in others. This may explain the lack of rela-
tionship between the number of astrocytes (revealed with 
anti-GFAP antibodies), and the expression of AQP1 in indi-
vidual cases. The present findings showing increased AQP1 
expression in selected astrocytes may represent a link be-
tween well-known arteriolar and capillary abnormalities [23, 
46] and specific responses to water transport in perivascular 
processes of astrocytes in AD.  
  The pathophysiological role of AQP1-expressing astro-
cytes in AD brains remains unknown. Increasing evidence 
indicate that AQP1 acts as a gas transporter (such as O2, 
CO2, and NO) [8, 20, 32]. In particular, AQP1, by transport-
ing NO out of endothelial cells and into vascular smooth 
muscle cells, plays a pivotal role in endothelium dependent 
vasorelaxation [32]. Because the production of NO and reac-
tive species is markedly enhanced in AD brains [4], the pos-
sibility exists that AQP1-expressing astrocytes with a great 
migratory capacity [93] act as a scavenger of these species in 
the cortex of AD. However, treatment with hydrogen perox-
ide did not affect the levels of AQP1 protein expression in 
human astrocytes culture, suggesting that these stimuli do 
not directly up-regulate AQP1 expression in astrocytes.  
  The present findings further support the idea that other 
abnormalities, including abnormal regulation of mechanisms 
involved in the control of water (and ion) fluxes, occur at 
early stages in AD. The recognition of events that precede 
hallmark lesions of AD is crucial for a better understanding 
of mechanisms that may favour the development and pro-
gression of the disease. Further studies, including the immu-
nohistochemical analysis of various disease stages, high-
resolution morphological and cell physiological analysis, are 
required to evaluate this hypothesis. 
4. PARKINSON’S DISEASE 
  Parkinson’s disease (PD), the most common neurodegen-
erative movement disorder, is characterized by an extensive 
and progressive loss of dopaminergic neurons in the pars 
compacta of substantia nigra. One of the pathological hall-
marks of PD is the presence of Lewy bodies, intracellular 
inclusions of aggregated -synuclein. Although the cause 
and pathogenesis of selective loss of dopamine neurons and 
the accumulation of -synuclein in PD remain elusive, grow-
ing lines of evidence from environmental risk factors and 
early-onset genetics point to a convergence between energy 
metabolism and the disposal of damaged proteins protea-
some system function can significantly contribute to the 
pathogenesis of PD [22]. 
4.1. Dopamine Regulation of AQP4 Expression 
  In the case of neurodegenerative diseases, neural stem 
cells that are present throughout adulthood will proliferate 
and differentiate into new neurons and ⁄or glia [47, 60]. 
There is evidence that these adult neural stem cells exhibit 
properties associated with glia both in vivo [26] and in vitro 
[35, 51]: for instance, they express GFAP, a marker for dif-
ferentiated astrocytes [21]. There is also evidence that 
changes in the number of GFAP positive cells are involved 
in neurodegenerative diseases such as PD [60]. The neuro-
transmitter dopamine (DA) stimulates proliferation of pro-
genitor cells, not only in the striatum, but also in the subven-
tricular zone of the adult brain [92]. In a recent study Kup-
pers and other authors provide evidence that DA regulates 
the proliferation of striatal astrocytes in culture and that these 
dopaminergic effects on proliferation are mediated by AQP4 
[49]. The results presented by these authors show a down-
regulation of AQP4 expression in striatal glial cells in vitro 
mediated by DA.  
  However, findings about the role of AQP4 in prolifera-
tion are few and contradictory. Whereas Saadoun and col-
leagues [82] reported no change in the proliferation of astro-
cytes cultured from transgenic mice lacking AQP4, Nicchia 
and colleagues [74] found a nearly 70% reduction in the cell 
number of cultivated astrocytes after short interference RNA 
(siRNA) treatment with RNA duplexes specific for AQP4. 
Therefore, this hypothesis needs to be corroborated by in 
vivo lesion studies. In addition, the expression of AQP4 in 
the lesioned striatum needs to be investigated, considering 
that in the substantia nigra an increase in AQP4 mRNA fol-
lowing 6-hydroxidopamine (6-OH-DA) lesion has been ob-
served [94]. 
  The observation of a down-regulation of astrocytes pro-
liferation by DA confirms and extends these assumption: 
neurodegenerative diseases correlated with perturbations of 
the dopaminergic transmission (such as PD) are linked to 
changes in the proliferation of astrocytes. These findings 
imply that modulation of AQP4 could be used therapeuti-
cally in the treatment of PD. 
4.2. Mitochondrial AQP9 in PD Brains 
  In the field of neurodegenerative diseases there is an   
intriguing although speculative link between AQP9 and PD 
[67]. In the brain, this water and solute channel is expressed 
in astrocytes, brain stem catecholaminergic neurons [6], and 
in subsets of midbrain dopaminergic and hypothalamic neu-
rons [5]. The observed enrichment of AQP9 in mitochondrial 
inner membranes could suggest a role in metabolic support 
of the neurons. In particular, it has been hypothesized that 
altered mitochondrial AQP9 in dopaminergic neurons may 
relate to their vulnerability in PD [3].  
  Because of the potential importance of mitochondrial 
AQP9 expression, Yang and colleagues [104] have system-
atically examined the predicted functional consequences of 
such expression. They have focused on functional transport 
measurements of mitochondrial inner membrane prepara-
tions: AQP9 function was studied by measurements of water 
and glycerol permeabilities in brain mitochondria [10, 90]. 
Permeabilities from rat brain mitochondria were compared 
with those from organs not expressing AQP9. Neither water 
nor glycerol permeability differed in mitochondria from the 
various tissues: in summary, these results provide functional 
evidence against a role for AQPs in mitochondria. Neverthe-
less, if AQP9 expression and activity may represent thera-
peutic targets to improve the treatment of PD, is to date an 
unresolved question. 
5. AMYOTROPHIC LATERAL SCLEROSIS 
  Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
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reflecting degeneration of motor neurones with intraneuronal 
ubiquitin-immunoreactive lesions in the primary motor   
cortex, corticospinal tracts, brain stem and spinal cord.   
Approximately two thirds of patients with typical ALS have 
a spinal form of the disease (limb onset) and present with 
symptoms related to focal muscle weakness and wasting. 
Paralysis is progressive and leads to death due to respiratory 
failure within 2-5 years. The majority of ALS cases are spo-
radic, but approximately 10% are hereditary (familial ALS; 
FALS). Some 15-20% of FALS cases have been associated 
with dominant mutations in the Cu/Zn superoxide dismutase 
(SOD1) gene [81]. 
5.1. Reduced Expression of AQP4 in Human Muscles 
with ALS 
  To date, the functional role of AQP4 in skeletal muscle 
tissue has not been fully clarified. In experimentally regener-
ating myofibers, AQP4 was not expressed under denervated 
conditions, whereas it was expressed when the muscle was 
innervated [42, 43]: these findings suggested that the expres-
sion of skeletal muscle AQP4 needs a nerve supply at the 
regenerating stage. However, in human muscles with neuro-
genic atrophy (e.g. ALS), there has been a very few data on 
the expression of AQP4; in human muscles with neurogenic 
atrophy, the expression of AQP4 was down-regulated. In rat 
muscles with experimental denervation, Jimi and colleagues 
[43] observed a remarkable and rapid decrease in AQP4 at 
the mRNA and protein levels confirmed by immunohisto-
chemical findings that reveal a decreased AQP4 staining on 
the surface of myofibers. This study of Jimi and colleagues 
showed that changes in the levels of AQP4 mRNA in mus-
cles with ALS and other neurogenic atrophies were essen-
tially the same, although there was a greater decrease of 
AQP4 in ALS than in other neurogenic atrophies. However, 
the role of innervation in transcriptional regulation of AQP4 
needs to be clarified.  
  Moreover, it is possible to postulate that AQP4 plays an 
important role in skeletal muscle cell homeostasis. However, 
water permeability analysis unexpectedly failed to show any 
differences between wild type and AQP4 knock-out mice in 
neuromuscular function, suggesting that AQP4 does not play 
a significant role in skeletal muscle physiology [57; 103]. A 
compensation of water channel function by other water 
channel proteins such as AQP3 [95] is another possibility. 
Further studies are needed to clarify the mechanism of   
transcriptional regulation by AQP proteins in denervated 
muscles. 
5.2. AQP4 as a Potential Marker of BBB Disruption in 
ALS Models 
  For years, investigators working in the field of ALS fo-
cused their research around motor neuronal death and subse-
quent pathways, nevertheless, studies of mutant superoxide 
dismutase 1 (SOD1) animal models, had revealed that also 
non-neuronal cells are important players in the disease proc-
ess [91]. Transgenic mice bearing FALS-associated human 
SOD1 (hSOD1) mutations show lower motor neuron degen-
eration and clinical symptoms reminiscent of human ALS 
[30, 102]. Over-expression of AQP4 at the glio-vascular 
swollen end-feet it has been observed in the transgenic rats 
SOD1 [73]: these findings are in agreement with the obser-
vation that AQP4 induction in perivascular astrocytes has 
been correlated to BBB breakdown and could serve as a 
marker of BBB integrity [88]. This concept was already ap-
proached by Kaiser and colleagues [44], who observed a 
progressive loss of Kir4.1 and a slight increase in AQP4 pro-
tein in the mouse ALS model. Kir4 co-localizes with AQP4 
channels and clusters around the microvasculature of the 
spinal cord; together these two proteins buffer K
+ and water 
away from the extracellular space to extrude it into blood 
vessels in the spinal cord [14] (Fig. (3)). However, AQP4 
over-expression is also noted in stacked glial processes di-
rectly in contact with motor neurons [73]. This observation, 
associated with findings that impaired K
+ buffering through 
loss of Kir.4 channel [44], could give an explanation to the 
understanding of the paracrine toxicity of motor neurons that 
is typical of ALS.  
  Taken together, these data corroborate evidences of 
AQPs involvement in BBB disruption in animal models of 








Fig. (3). Co-localization between Kir4 and AQP4 in adult mouse spinal cord. Kir4.1 immunolabeling (panel 2, red) showed clustering on 
astrocytic endfeet (panel 1, green). (panel 3) AQP4 (magenta) immunoreactivity on EGFP/GFAP-positive astrocytes predominantly labeling 
astrocytic endfeet. (panel 4) Merged images of (panels 1-3). Arrowheads point to an astrocytic endfoot co-labelled by Kir4.1 and AQP4. 
Note that the astrocytic cell body (arrow) was only weakly labelled by Kir4.1 and AQP4, whereas the expression of both membrane proteins 
was predominantly targeted to the astrocytic network and astrocytic endfeet. Figures from Kaiser et al., [44], reprinted with permission of 
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disease process by spreading inflammation within the CNS 
and so weakening susceptible neuronal functions. Further 
confirmations have to be obtained from human disease sam-
ples and may lead to therapeutic strategies fog restoring the 
BBB integrity in ALS.  
6. TRASMISSIBLE SPONGIFORM ENCEPHALO-
PATHIES 
  Prion diseases, also called TSEs are cerebral amyloidosis 
characterized by deposition and accumulation of a pathologic 
protein (PrPres), neuronal loss, gliosis, and spongiform 
change [27, 36]. The spongiform change, a cardinal lesion in 
these diseases, consists of the formation of rounded vacuoles 
within the neuropil that are swollen neuronal and astrocytic 
cell processes with disrupted membranes, often in contact 
with synaptic structures [55]. Little is known about the 
mechanisms which participate in the vacuolization of the 
neuropil [28]. However, spongiform change is likely the re-
sult of abnormal membrane homeostasis and increased water 
content within swollen cell processes. Therefore, exploration 
of mechanisms regulating water homeostasis seems to be a 
promising step toward increased understanding of the patho-
genesis of TSEs. 
6.1. AQP1 and AQP4 Brain Expression in TSE 
  Enhanced expression of AQP4 in Creutzfeldt-Jakob dis-
ease (CJD) was first reported by Iwasaki’s laboratory [37]. 
Furthermore, Rodriguez and colleagues [79] analyzed AQP1 
and AQP4 expression in the cerebral cortex of CJD patients 
compared to that in cases with AD and diffuse Lewy body 
disease (DLB). Significant increased expression levels of 
AQP1 and AQP4 were seen in CJD, but not in advanced AD 
and DLB cases. Immunohistochemistry revealed that AQP1 
and AQP4 were expressed in astrocytes in diseased cases. 
Moreover, the findings of the present study indicate that in-
creased AQP4 immunoreactivity is not restricted to the early 
stage of CJD but also occurs at later stages in the lesions of 
status spongiosus. 
  In a similar study, instead, Iwasaki and colleagues [38] 
compared cases of subacute spongiform encephalopathy 
(SSE) and panencephalopathic (PE)-type CJD. Increased 
AQP4 immunoreactivity was observed in all these patients, 
particularly in the cerebral neocortex and cerebellar cortex. 
AQP4 immunoreactivity was present in the cell bodies and 
processes of protoplasmic astrocytes in SSE and around cell 
bodies and processes of hypertrophic astrocytes in PE-type 
CJD.  
  Together, these findings show increased expression of 
water channels in the brain in human and animal prion dis-
eases that may have implications in the regulation of water 
transport in astrocytes and may account for an imbalance in 
water and ion homeostasis. Although change in AQPs ex-
pression may be a secondary change of TSE pathologies, it 
may reflect important aspects of astrocytic pathology associ-
ated with these diseases. 
CONCLUSIONS 
  Water transport is a fundamental process contributing to 
human physiology and pathophysiology. The importance of 
AQPs in the physiology of water and solute movement in the 
CNS is now clear. Therefore, targeted pharmacological 
modulation of water and solute transport using AQPs would 
appear to provide novel opportunities for therapeutic inter-
ventions in a variety of human disorders involving CNS, like 
neurodegenerative diseases. 
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